Back to Search
Start Over
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial
- Source :
- The Lancet Gastroenterology & Hepatology; June 2019, Vol. 4 Issue: 6 p454-465, 12p
- Publication Year :
- 2019
-
Abstract
- Cytotoxic chemotherapy is generally ineffective in patients with hepatocellular carcinoma. We assessed the intravenous perfusion of doxorubicin-loaded nanoparticles in patients with hepatocellular carcinoma in whom previous sorafenib therapy had failed.
Details
- Language :
- English
- ISSN :
- 24681253
- Volume :
- 4
- Issue :
- 6
- Database :
- Supplemental Index
- Journal :
- The Lancet Gastroenterology & Hepatology
- Publication Type :
- Periodical
- Accession number :
- ejs49978794
- Full Text :
- https://doi.org/10.1016/S2468-1253(19)30040-8